Related Experiment Video

Updated: Aug 19, 2026

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
07:12

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Published on: July 7, 2016

B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides

Bernd Jahrsdorfer1, Lars Mühlenhoff, Sue E Blackwell

  • 1Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 5, 2005
PubMed

Insights

Most B-cell cancers, except plasmacytoma, respond to CpG oligodeoxynucleotides by increasing key molecules and proliferating. B-cell chronic lymphocytic leukemia and marginal zone lymphoma showed the strongest activation, suggesting potential for targeted therapy.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Toll-like receptor 9 (TLR9) recognizes CpG motifs in microbial DNA, a mechanism relevant to B cell function.
  • Synthetic CpG oligodeoxynucleotides are under investigation as a therapeutic strategy for B cell non-Hodgkin's lymphoma (NHL).
  • Limited data exists on the differential sensitivity of various primary malignant B cell types to CpG oligodeoxynucleotides.

Purpose of the Study:

  • To investigate the in vitro responsiveness of primary malignant B cells from different non-Hodgkin's lymphoma entities to CpG oligodeoxynucleotides.
  • To assess the impact of CpG oligodeoxynucleotides on B cell activation, proliferation, and apoptosis in various B-cell malignancies.

Main Methods:

  • Analysis of CpG oligodeoxynucleotide sensitivity in 41 patient-derived primary tumor samples of B-cell malignancies.
  • Measurement of B cell activation markers (costimulatory, antigen-presenting molecules, CD20) and proliferation.
  • Quantification of Toll-like receptor 9 (TLR9) mRNA expression in malignant B cells.

Main Results:

  • Most B-cell malignancies, including B-cell chronic lymphocytic leukemia (B-CLL) and marginal zone lymphoma, demonstrated significant activation and proliferation upon CpG oligodeoxynucleotide stimulation.
  • B-CLL and marginal zone lymphoma exhibited the strongest responses, while small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and large cell lymphoma showed intermediate sensitivity.
  • Plasmacytoma cells lacked TLR9 mRNA and did not respond to CpG oligodeoxynucleotides; CpG-induced proliferation in sensitive B-cell malignancies was weaker than in normal B cells and led to increased apoptosis in B-CLL.

Conclusions:

  • Significant heterogeneity exists in the responsiveness of B-cell malignancies to CpG oligodeoxynucleotides.
  • The differential sensitivity, particularly the strong response in B-CLL and marginal zone lymphoma, warrants further investigation.
  • Stratifying patients based on CpG oligodeoxynucleotide sensitivity in clinical trials may enhance therapeutic efficacy for non-Hodgkin's lymphoma.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...